PL88871B1 - - Google Patents
Download PDFInfo
- Publication number
- PL88871B1 PL88871B1 PL1969135222A PL13522269A PL88871B1 PL 88871 B1 PL88871 B1 PL 88871B1 PL 1969135222 A PL1969135222 A PL 1969135222A PL 13522269 A PL13522269 A PL 13522269A PL 88871 B1 PL88871 B1 PL 88871B1
- Authority
- PL
- Poland
- Prior art keywords
- parts
- weight
- glycofuranoside
- amount
- weight per
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 34
- -1 polyoxyethylene Polymers 0.000 claims description 14
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 13
- 239000000391 magnesium silicate Substances 0.000 claims description 13
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 13
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 13
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 229920003023 plastic Polymers 0.000 claims description 6
- 239000004033 plastic Substances 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 5
- 239000001913 cellulose Substances 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920001800 Shellac Polymers 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 2
- 239000004208 shellac Substances 0.000 claims description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
- 229940113147 shellac Drugs 0.000 claims description 2
- 235000013874 shellac Nutrition 0.000 claims description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000003463 adsorbent Substances 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000008119 colloidal silica Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000002966 varnish Substances 0.000 description 3
- ULLNJSBQMBKOJH-JPHCZMGXSA-N (2s,3r,4r,5r)-5-[(1r)-1,2-bis(phenylmethoxy)ethyl]-2-ethoxy-4-phenylmethoxyoxolan-3-ol Chemical compound C([C@H]([C@H]1O[C@@H]([C@@H]([C@H]1OCC=1C=CC=CC=1)O)OCC)OCC=1C=CC=CC=1)OCC1=CC=CC=C1 ULLNJSBQMBKOJH-JPHCZMGXSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960003567 tribenoside Drugs 0.000 description 2
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RMRFFCXPLWYOOY-UHFFFAOYSA-N allyl radical Chemical compound [CH2]C=C RMRFFCXPLWYOOY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1170468 | 1968-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL88871B1 true PL88871B1 (enExample) | 1976-10-30 |
Family
ID=4376070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL1969135222A PL88871B1 (enExample) | 1968-08-05 | 1969-08-04 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US3594474A (enExample) |
| AT (1) | AT290731B (enExample) |
| BE (1) | BE737053A (enExample) |
| BG (1) | BG17466A3 (enExample) |
| BR (1) | BR6911321D0 (enExample) |
| CA (1) | CA938889A (enExample) |
| CY (1) | CY790A (enExample) |
| DE (1) | DE1938108C3 (enExample) |
| DK (1) | DK123912B (enExample) |
| FI (1) | FI50058C (enExample) |
| FR (1) | FR2015053A1 (enExample) |
| GB (1) | GB1259387A (enExample) |
| IE (1) | IE33246B1 (enExample) |
| IL (1) | IL32673A (enExample) |
| IT (1) | IT1035508B (enExample) |
| MY (1) | MY7500079A (enExample) |
| NL (1) | NL162837C (enExample) |
| NO (1) | NO129183B (enExample) |
| OA (1) | OA03604A (enExample) |
| PL (1) | PL88871B1 (enExample) |
| RO (1) | RO57881A (enExample) |
| SE (1) | SE363735B (enExample) |
| SU (1) | SU409407A3 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4195078A (en) * | 1979-03-09 | 1980-03-25 | Eli Lilly And Company | Nabilone granulation |
| DE3773926D1 (de) * | 1987-07-22 | 1991-11-21 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung. |
-
1969
- 1969-07-22 IL IL32673A patent/IL32673A/en unknown
- 1969-07-23 CA CA057745A patent/CA938889A/en not_active Expired
- 1969-07-25 US US845038A patent/US3594474A/en not_active Expired - Lifetime
- 1969-07-26 DE DE1938108A patent/DE1938108C3/de not_active Expired
- 1969-07-29 FR FR6925823A patent/FR2015053A1/fr not_active Withdrawn
- 1969-07-29 IE IE1051/69A patent/IE33246B1/xx unknown
- 1969-07-30 BG BG012772A patent/BG17466A3/xx unknown
- 1969-07-30 FI FI692257A patent/FI50058C/fi active
- 1969-07-31 GB GB1259387D patent/GB1259387A/en not_active Expired
- 1969-07-31 CY CY790A patent/CY790A/xx unknown
- 1969-08-04 SU SU1356872A patent/SU409407A3/ru active
- 1969-08-04 NO NO03188/69A patent/NO129183B/no unknown
- 1969-08-04 AT AT748569A patent/AT290731B/de not_active IP Right Cessation
- 1969-08-04 BE BE737053D patent/BE737053A/xx not_active IP Right Cessation
- 1969-08-04 IT IT39194/69A patent/IT1035508B/it active
- 1969-08-04 SE SE10870/69A patent/SE363735B/xx unknown
- 1969-08-04 NL NL6911864.A patent/NL162837C/xx not_active IP Right Cessation
- 1969-08-04 DK DK418069AA patent/DK123912B/da not_active IP Right Cessation
- 1969-08-04 PL PL1969135222A patent/PL88871B1/pl unknown
- 1969-08-05 OA OA53697A patent/OA03604A/xx unknown
- 1969-08-05 BR BR211321/69A patent/BR6911321D0/pt unknown
- 1969-08-05 RO RO@@A patent/RO57881A/ro unknown
-
1970
- 1970-09-18 US US73606A patent/US3655870A/en not_active Expired - Lifetime
-
1975
- 1975-12-30 MY MY79/75A patent/MY7500079A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2015053A1 (enExample) | 1970-04-24 |
| NO129183B (enExample) | 1974-03-11 |
| AT290731B (de) | 1971-06-11 |
| NL6911864A (enExample) | 1970-02-09 |
| SU409407A3 (enExample) | 1973-11-30 |
| BE737053A (enExample) | 1970-02-04 |
| IL32673A0 (en) | 1969-09-25 |
| MY7500079A (en) | 1975-12-31 |
| DE1938108A1 (de) | 1970-02-26 |
| IE33246L (en) | 1970-02-05 |
| DK123912B (da) | 1972-08-21 |
| GB1259387A (enExample) | 1972-01-05 |
| NL162837C (nl) | 1980-07-15 |
| US3594474A (en) | 1971-07-20 |
| SE363735B (enExample) | 1974-02-04 |
| OA03604A (fr) | 1971-03-30 |
| IT1035508B (it) | 1979-10-20 |
| IL32673A (en) | 1973-11-28 |
| IE33246B1 (en) | 1974-05-01 |
| NL162837B (nl) | 1980-02-15 |
| CA938889A (en) | 1973-12-25 |
| CY790A (en) | 1976-06-01 |
| FI50058C (fi) | 1975-12-10 |
| DE1938108C3 (de) | 1974-01-03 |
| BR6911321D0 (pt) | 1973-02-13 |
| RO57881A (enExample) | 1974-11-15 |
| US3655870A (en) | 1972-04-11 |
| BG17466A3 (bg) | 1973-11-10 |
| FI50058B (enExample) | 1975-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0069097B1 (en) | Pharmaceutical mixture | |
| AU674175B2 (en) | Oral compositions containing 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxyaldehyde-o- methyl-oxime | |
| CZ287260B6 (en) | Gastric-protected stable omeprazole preparation in the form of micro-granules and process for preparing thereof | |
| JPS63154620A (ja) | スフエロイド | |
| KR0177493B1 (ko) | 단사정계 결정구조를 갖고 감열, 감광 및 감습성이 있는 활성성분을 함유하는 정제의 제조방법 | |
| JPS5829717A (ja) | 医薬用賦形剤 | |
| EP0559645A1 (en) | Composition for solid pharmaceutical preparations containing active vitamins d 3? and process for preparation thereof | |
| JPS6261916A (ja) | 持続性製剤 | |
| JP4387192B2 (ja) | Ｓ−アデノシルメチオニンを含む錠剤の調製方法 | |
| PL88871B1 (enExample) | ||
| CN103385863B (zh) | 一种薁磺酸钠缓释制剂 | |
| JPS6335526A (ja) | ポリマ−処理イオン交換樹脂 | |
| CN111110641B (zh) | 一种左氧氟沙星片剂组合物及其制备方法 | |
| JPH11335302A (ja) | 安定な医薬組成物 | |
| AU2019348630B2 (en) | A process for the preparation of a modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride | |
| CZ295584B6 (cs) | Farmaceutická kompozice obsahující jako účinnou látku platinový komplex a způsob výroby této kompozice | |
| US4010275A (en) | Treatment of osteoarthritis | |
| Todoran et al. | DEVELOPMENT OF A MODIFIED-RELEASE PELLETS FORMULATION WITH METOPROLOL TARTRAT AND KINETIC ASPECTS OF IN VITRO RELEASE | |
| JPH03193733A (ja) | テオフィリンの徐放性製剤 | |
| JPS615010A (ja) | 水素添加麦角アルカロイド徐放性製剤及びその製法 | |
| CS251786B2 (en) | Method of pharmaceutical preparations production with depot effect | |
| CN118021736A (zh) | 一种奥卡西平固体制剂及其制备方法和应用 | |
| JPS6024765B2 (ja) | セフアレキシンの持続性製剤の製造方法 | |
| US3836644A (en) | Treatment of wounds | |
| RS52818B (sr) | Farmaceutska formulacija sa kontrolisanim otpuštanjem koja sadrži natrijum alginat i natrijum kalcijum alginat |